Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approves Apadaz for Acute Pain Relief

KemPharm, Inc. news release; 2018 Feb 23

KemPharm, Inc., has announced that the US Food and Drug Administration (FDA) approved its New Drug Application (NDA) for Apadaz for the short-term (no >14 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. KemPharm, Inc.’s corporate headquarters is located in Coralville, IA.

Indications: Apadaz is an immediate release (IR) combination of KemPharm’s prodrug, benzhydrocodone, and acetaminophen (APAP).

Dosage strengths/administration: Immediate-release tablets: 6.12 mg benzhydrocodone (equivalent to 6.67 mg benzhydrocodone hydrochloride) and 325 mg acetaminophen. Patients should use the lowest effective dose for the shortest duration consistent with individual patient treatment goals. Individualized dosing is based on the severity of pain, patient response, prior analgesic experience, and risk factors for addiction, abuse, and misuse.

Adverse reactions: The most common adverse reactions (>5%) are nausea, somnolence, vomiting, constipation, pruritus, dizziness, and headache.


KemPharm announces FDA approval of Apadaz (benzhydrocodone and acetaminophen) for short-term management of acute pain. [news release]. Coralville, IA: KemPharm, Inc. February 23, 2018. Accessed March 15, 2018.

This Week's Must Reads

Examining Brain Markers for Late-Onset Epilepsy, Neurology; ePub 2019 Jan 25; Johnson, et al

Hearing Loss Linked Cognitive Decline Risk in Men, Alzheimers Dement; ePub 2019 Jan 29; Curhan, et al

Brain Cholesterol Metabolism and PD Examined, Mov Disord; ePub 2019 Jan 25; Huang, et al

Sleep Behavior Disorder, Clinical Progression in PD, Parkinsonism Relat Disord; ePub 2019 Jan 29; Duarte Folle, et al

Spontaneous Subarachnoid Hemorrhage During Pregnancy, J Stroke Cerebrovasc Dis; ePub 2019 Jan 30; Limaye, et al

Must Reads in FDA Actions

FDA Approves Ajovy for Migraine in Adults, Teva Pharmaceutical news release; 2018 Sep 14

FDA Approves Tiglutik for Treatment of ALS, ITF Pharma news release; 2018 Sep 6

FDA Approves Diacomit for Treatment of Seizures, Biocodex news release; 2018 Aug 23